[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unresectable-metastatic-melanoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unresectable-metastatic-melanoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100659831","detection-of-the-braf-v600e-mutation-in-liquid-biopsy-using-the-crisprcas12a-system-100659831",false,"NCT07870265","Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR\u002FCas12a System","BRAF SENS","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Subject willing and able to provide written informed consent for biological sample collection.\n* Ability to communicate effectively with the investigator in the local language, as well as the ability to understand and comply with study requirements.\n* Histologically confirmed malignant melanoma.\n* Radiologically or histologically confirmed disease relapse.\n* Feasibility\u002Fpossibility of peripheral blood sampling for ctDNA analysis.\n* Documented, known \\*BRAF\\* mutation status (wild-type vs. V600E).\n\nExclusion Criteria:\n\n* Operable disease relapse.\n* Age under 18 years.\n* Pregnant or breastfeeding women.\n* Patients receiving palliative care with an estimated life expectancy ≤ 3 months.\n* Severe alcohol and\u002For drug abuse during therapy.\n* Inability to obtain a valid biological sample for molecular analysis","ALL","18 Years",{"count":19,"type":20},17,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable metastatic melanoma after disease relapse. The method will be based on a CRISPR\u002FCas12a system combined with isothermal amplification and endpoint electrochemical detection using electrode chips and low-cost instrumentation.",[26,27],"Unresectable Metastatic Melanoma","BRAF V600E Mutation",[29,30,31,32,33],"BRAF V600","Metastatic melanoma","Liquid biopsy","Circulating tumor DNA (ctDNA)","CRISPR\u002FCas12a","RECRUITING","2026-10-06",{"date":37,"type":38},"2026-10-13","ACTUAL",{"date":40,"type":20},"2026-10-20",{"date":42,"type":20},"2027-12-20",{"name":44,"class":45},"Masaryk Memorial Cancer Institute","OTHER"]